Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2025)
Vivos Therapeutics (VVOS) has disclosed Total Liabilities for 7 consecutive years, with $23.1 million as the latest value for Q3 2025.
- On a quarterly basis, Total Liabilities rose 200.86% to $23.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.1 million, a 200.86% increase, with the full-year FY2024 number at $7.3 million, down 28.97% from a year prior.
- Total Liabilities was $23.1 million for Q3 2025 at Vivos Therapeutics, up from $21.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $23.1 million in Q3 2025 to a low of $6.9 million in Q1 2025.
- A 5-year average of $10.5 million and a median of $9.5 million in 2022 define the central range for Total Liabilities.
- Peak YoY movement for Total Liabilities: soared 403.67% in 2021, then tumbled 38.74% in 2025.
- Vivos Therapeutics' Total Liabilities stood at $8.2 million in 2021, then grew by 9.44% to $8.9 million in 2022, then grew by 15.7% to $10.3 million in 2023, then decreased by 28.97% to $7.3 million in 2024, then surged by 215.31% to $23.1 million in 2025.
- Per Business Quant, the three most recent readings for VVOS's Total Liabilities are $23.1 million (Q3 2025), $21.4 million (Q2 2025), and $6.9 million (Q1 2025).